INDP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
INDP is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The pre-market price at 2.8 is still below the pivot (3.307) and below resistance levels, but the technical setup is weak, there is no bullish proprietary signal, no recent news catalyst, and the latest financials remain deeply unprofitable. For an impatient investor, this is not a strong entry today.
Technical trend is weak to neutral. MACD histogram is negative and expanding, which points to ongoing downside momentum. RSI_6 at 38.5 is neutral but closer to oversold than overbought, indicating lack of buyer strength. Moving averages are converging, so there is no clear bullish trend reversal yet. Price at 2.8 is below the pivot of 3.307 and just above S1 of 2.906 is not confirmed by momentum, suggesting the stock is still in a fragile zone rather than a clean buy setup.
["No recent news in the last week", "Pre-market trading is active, which can sometimes create opportunity if momentum improves", "Stock pattern analysis suggests a slightly positive next-week probability at 0.84%"]
["No AI Stock Picker signal today", "No SwingMax signal recently", "MACD is negative and worsening", "Revenue is still 0, showing no commercial growth", "Net income remains deeply negative", "EPS declined sharply year over year", "Hedge funds are neutral", "Insiders are neutral", "No recent congress trading data", "Pattern-based forecast shows a negative next-month expectation of -3.83%"]
In 2025/Q3, Indaptus Therapeutics reported revenue of 0, unchanged year over year, so there is no visible top-line growth. Net income was -2,975,117, still negative and down 3.06% YoY. EPS was -2.98, down 67.04% YoY, which shows worsening per-share performance. Gross margin was 0, indicating the company is still not generating meaningful operating profitability.
No analyst rating or price target change data was provided, so there is no clear Wall Street upgrade/downgrade trend to support a bullish view. Based on the available information, Wall Street pros would likely be cautious: the pros are that the stock is near lower technical levels and could bounce if momentum improves, while the cons are weak financials, no recent catalyst, no favorable insider/hedge fund trend, and no proprietary buy signal. Overall analyst sentiment cannot be confirmed, but the available evidence leans cautious to bearish.
